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Abstract 
Background and aim: Trigeminal neuralgia (TN) is a rare orofacial disorder characterized 
by severe unilateral paroxysmal pain in the region of the fifth cranial nerve. Clinical 
guidelines recommend carbamazepine (only US Food and Drug Administration–approved 
drug for TN) and oxcarbazepine as first-line therapies. We utilized the US Truven Health 
MarketScan
®
 database to examine treatment patterns among patients with TN. 
Methods: Included patients were aged ≥18 years, newly diagnosed with TN (≥2 TN 
diagnoses ≥14 days apart; no diagnosis in the prior year), continuously enrolled 1 year pre-
index, with ≥3 years’ follow-up post-index. We assessed utilization of selected 
pharmacotherapies (carbamazepine, oxcarbazepine, pregabalin, gabapentin, baclofen, 
duloxetine, topiramate), surgery (posterior fossa, radiosurgery), and injections (peripheral 
anesthetic injections, Gasserian ganglion procedures) for TN. 
Results: 3685 patients were included (2425 commercial, 1260 Medicare; 71.8% female; 
mean[SD] age, 59[15] years). Overall, 72.5% of patients received at least 1 studied 
medication, most commonly carbamazepine (51.7%) or gabapentin (48.6%). Sixty-five 
percent of pharmacologically treated patients had ≥2 treatment episodes; 41.6% had ≥3 
(defined by a change in pharmacotherapy [monotherapy/combination] regimen). Overall, 
12.3% had surgery and 7.3% injections; 42.9% received opioids for TN. 
Conclusions: In the 3 years after diagnosis, patients with TN in the United States receive a 
variety of pharmacological treatments, including opioids, despite carbamazepine being the 
only approved medication. A notable proportion utilize surgeries/injections. A high 
proportion of pharmacologically treated patients receive multiple treatment episodes, 
suggesting frequent therapy switching, perhaps due to suboptimal efficacy/tolerability. Our 
data suggest a high burden of illness associated with TN. 
Keywords [3 to 5 per journal guidelines] 
Trigeminal neuralgia; pharmacological treatment; surgery; treatment patterns; claims analysis  
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INTRODUCTION 
Trigeminal neuralgia (TN) is an orofacial pain disorder characterized by severe 
shock-like recurrent pain occurring within the region of the fifth cranial nerve.
1
 The condition 
is considered rare, with estimates for annual incidence ranging from 4.7 to 28.9 per 100,000 
persons.
2-5
 However, the patient burden of TN is substantial owing to the severity of the pain, 
which may worsen or become more prolonged over time.
6,7
 In one study, almost 60% of 
patients scored the intensity of TN paroxysmal stabbing pain as “the worst possible pain.”8 
There is evidence that TN-associated pain can lead to disability, depression, and anxiety, 
having a significant impact on patient’s quality of life, as well as indirect costs to society 
resulting from work absenteeism.
6,7
 
Clinical guidelines recommend carbamazepine, the only medication currently 
approved by the US Food and Drug Administration (FDA) for TN, and oxcarbazepine (a 
keto-analog of carbamazepine), both anticonvulsants, as first-line treatments for TN.
9
 While 
there is evidence to support the use of carbamazepine for pain relief in TN (number need to 
treat [NNT] of 2)
10
, its use must be considered in light of a poor tolerability profile and 
adverse effects that can include dizziness, liver damage, and cognitive impairment (number 
needed to harm for carbamazepine withdrawal of 24, 95% CI 14 –112).10,11,12-16 Further, 
caution is recommended in patients with comorbidities due to the potential for drug 
interactions.
17
 Oxcarbazepine has greater tolerability and a reduced risk of drug interactions 
than carbamazepine, but its efficacy has not been confirmed in well-conducted randomized 
controlled trials.
10
 Other pharmacological treatments used in clinical practice for TN and 
neuropathic pain conditions include the anticonvulsants gabapentin (NNT of 8.0 in 
postherpetic neuralgia and NNT of 5.9 in painful diabetic neuropathy),
18
 pregabalin 
(combined NNT of 4.2 in post-herpetic neuralgia and painful diabetic neuropathy),
19
 
lamotrigine (NNT of 2.1 in TN as an add-on treatment),
20
 and topiramate (NNT of 7.4 in 
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painful diabetic neuropathy);
19
 the skeletal muscle relaxant baclofen (NNT of 1.4);
20
 and the 
selective serotonin reuptake inhibitor duloxetine; however, these treatments are not 
specifically indicated for TN and the evidence for their use in treating representative TN 
patient populations is limited.
9,10,21-23
 Previous studies have reported that not all patients with 
TN receive pharmacological treatment, but that among treated patients, carbamazepine was 
the most frequently prescribed first-line drug for TN in the United Kingdom and the 
Netherlands.
5,24
 
Guidelines recommend that surgery should be considered for patients refractory to 
medical treatment,
9
 as indicated by increased likelihood of receiving ≥2 pharmacological 
treatments.
25
 Surgical procedures used for TN treatment in clinical practice include 
percutaneous procedures on the Gasserian ganglion, stereotactic radiosurgery, and 
microvascular decompression.
9,10,23
 However, high-quality evidence to support and guide best 
practice remains limited. Additionally, recent studies have suggested that botulinum toxin 
(Botox, Allergan, Irvine, CA) may have some efficacy in the treatment of TN pain.
26
 
Peripheral nerve injections (distal to the Gasserian ganglion), including local anesthetics or 
neurolytic agents such as alcohol, are also sometimes used, but evidence for their efficacy is 
either negative or insufficient.
9
 While opioids are commonly used in clinical practice to treat 
severe pain,
27
 there is a lack of evidence on the efficacy of opioids to treat TN-related pain, 
and a Cochrane review has highlighted uncertainty regarding the use of opioids for 
neuropathic pain in general, owing to limited evidence as well as concerns about addiction 
and side effects.
28
 Of note, opioid abuse is considered a growing epidemic in the United 
States, leading the FDA to develop an action plan to reduce the impact of such abuse.
29
 
Given the absence of high-quality evidence, treatment approaches for TN vary, and 
real-world treatment patterns among patients with TN are poorly understood. An improved 
understanding of the treatment of TN in clinical practice may help to identify unmet needs 
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within this population and inform health care decision making. We therefore undertook a 
retrospective claims database analysis to examine the real-world pharmacological and 
nonpharmacological treatment patterns among a cohort of patients newly diagnosed with TN 
enrolled in commercial and Medicare managed care or supplemental health insurance plans in 
the United States. 
METHODS 
Study Design and Data Source 
This was a retrospective analysis utilizing claims data from the Truven Health 
MarketScan
®
 (Truven Health, Ann Arbor, MI) commercial and Medicare claims databases, 
from 2010 to quarter 3 2015. The databases contain administrative claims and eligibility 
records for >100 million commercially insured individuals and 8 million Medicare 
beneficiaries from all regions in the United States. These include medical services claims 
(excluding dental) in inpatient and outpatient settings, with associated procedures and 
diagnosis codes, which have been submitted for reimbursement. They also contain 
information on pharmacy dispensing claims, as well as demographic information including 
age, sex, health plan type, and region of residence. Commercial plans in MarketScan are 
typically employer sponsored to cover employees and their dependents, while Medicare is 
government funded and includes patients ≥65 years of age. Medicare enrollees in MarketScan 
are covered by Medigap or Medicare Managed Care Plans (eg, Medicare Advantage Plans), 
which generally include benefits that Original Medicare does not cover (such as copayments, 
deductibles, and prescription drug coverage). The databases are compliant with the Health 
Insurance Portability and Accountability Act, and all data are deidentified. 
Patient Population  
Patients were included in the analysis if they were ≥18 years of age and newly 
diagnosed with TN during the study period. Patients were required to have ≥2 claims with a 
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TN diagnosis code (International Classification of Diseases, Ninth Revision (ICD-9) 350.1, 
350.8; ICD10 G500) that were dated ≥14 days apart. The date of the first claim was 
designated as the index date. Newly diagnosed patients were defined as those without a 
diagnosis for TN in the year before index. Patients also had to be continuously enrolled for 1 
year pre index, and have ≥3 years’ follow-up post index, to ensure a sufficient duration to 
capture treatment patterns and switching over time (Fig. 1). 
Outcome Measures 
Patient Demographics and Comorbidities 
Demographic information was collected at the index date (first TN claim). 
Comorbidities, including other chronic pain conditions, were based on specified diagnosis 
codes associated with claims in the 1 year before index (listed in Table, Supplemental Digital 
Content 1, http://links.lww.com/CJP/A478 ).  
Pharmacological Treatments  
We evaluated the utilization of pharmacological treatments based on prescription fills 
over the 3 years on or post index. The following 7 pharmacological treatments were 
considered medications of interest, and were identified in the database by National Drug 
Codes: carbamazepine, oxcarbazepine, pregabalin, gabapentin, baclofen, duloxetine, and 
topiramate. These pharmacological treatments were identified as commonly used for TN 
treatment in clinical practice, based on clinical experience and overall volume of 
prescriptions for newly diagnosed patients with TN in the database. Because outpatient 
pharmacy claims do not include diagnosis information, in order to attribute prescription fills 
to the management of TN, there had to be a medical claim with a TN diagnosis up to 30 days 
before or 7 days after the first prescription fill for each of the 7 medications. Subsequent 
prescription fills of the same medication were not required to have a medical claim with a TN 
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diagnosis, because patients can typically receive a supply of (nonopioid) medications for up 
to 12 months without a face-to-face physician consultation (ie, no medical claim for TN). 
The frequency of change of pharmacological treatments was evaluated according to 
treatment episodes (based on analysis of the 7 medications of interest listed above, and 
excluding opioid use). A treatment episode was defined as any unique pharmacological 
treatment regimen (monotherapy or combination), with the end of each episode defined by a 
change in regimen (add-on, switch, or discontinuation; for definitions see Table, 
Supplemental Digital Content 2, http://links.lww.com/CJP/A479 ). Discontinuation was 
defined as a >90-day gap in supply; a 90-day gap was required to ensure true discontinuation 
versus extension of the supply due to missed doses, and is consistent with the definition of 
discontinuation used in other claims analyses.
30-34
 
Surgery and Injections 
Utilization of nonpharmacological treatments, in the form of surgery and injections, 
was evaluated over the 3 years post index. Surgeries and injections were identified by unique 
procedure codes (Table, Supplemental Digital Content 3, http://links.lww.com/CJP/A480 ). 
Surgery included posterior fossa surgery (eg, microvascular decompression) and 
radiosurgery, while injections included peripheral anesthetic injections and ablative 
procedures at the Gasserian ganglion level. Botulinum toxin was captured under peripheral 
anesthetic injections. The surgeries and injections of interest were selected as being used for 
the treatment of TN in clinical practice, based on clinical experience and review of the 
literature.
35,36
 To be included in the analysis, the surgeries and injections were required to 
have a TN diagnosis in one of the diagnosis fields (primary diagnosis of TN for inpatient 
claims, or any TN diagnosis for outpatient claims).  
Opioids 
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Patterns of opioid use were assessed, but were not included for the analysis of 
treatment episodes because opioids are not considered to be a standard-of-care maintenance 
treatment for TN, and effectiveness in other neuropathic pain conditions is uncertain. To be 
considered TN related, there had to be a medical claim with a TN diagnosis up to 30 days 
before or 7 days after any opioid prescription fill. Because opioids are commonly used to 
treat pain conditions other than TN, we required that all opioid fills be associated with a TN 
medical claim (in contrast to only the first fill for other medications). 
All analyses were reported for all eligible patients and stratified by insurance type 
(commercial vs. Medicare) in order to take into account the age difference between the 2 
populations, which has an implication for comorbidities and treatment patterns, and because 
the overall age distribution is not representative of the general US population (the Medicare 
population in the Truven Health MarketScan database accounts for only a small proportion of 
those ≥65 years of age). However, reporting of data in the text is for the combined overall 
population, except in cases where there were notable differences between groups. All data are 
reported as descriptive statistics. 
RESULTS 
Patient Population 
A total of 3685 patients were included in the analysis, of whom 2425 were enrolled in 
commercial plans, and 1260 in Medicare plans (Fig. 1).  
Demographics and Comorbidities  
Mean (SD) age at first TN diagnosis was 59.0 (15.3) years for the overall population; 
71.8% of patients were female (Table 1). As expected, owing to differences in the age of the 
populations, the proportions of patients with cerebrovascular disease, hypertension, and 
diabetes were higher in the Medicare than the commercial population. The proportion with 
multiple sclerosis (MS) was higher in the commercial population. Among the most common 
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pain comorbidities, osteoarthritis, low back pain, and stroke-associated pain were more 
frequent in the Medicare population, while migraine and fibromyalgia were more frequent 
among commercial patients. The highest proportion of the overall patient population lived in 
the south, with a higher proportion of commercial than Medicare patients. The proportion of 
patients living in North Central was higher among the Medicare population. Overall, the 
lowest proportion of patients lived in the west. (Table 1). 
Overall Pharmacological and Non-pharmacological Treatment Utilization 
Overall, almost three-quarters of patients received ≥1 pharmacological treatment, 
surgery, or injection of interest during the 3 years following TN diagnosis (a quarter had a 
diagnosis of TN, but received none of the pharmacological or nonpharmacological treatments 
of interest during the study period; Table 2). The majority (84.4%) of treated patients 
received pharmacological monotherapy as their first treatment; 12.0% were treated first with 
combination pharmacological therapy (ie, polypharmacotherapy) and 3.6% with surgery 
(posterior fossa surgery or radiosurgery). For the second and third treatments, the proportions 
with polypharmacy and surgery increased, while monotherapy decreased (Table, 
Supplemental Digital Content 5, http://links.lww.com/CJP/A482 ). 
Pharmacological Treatment 
Almost three-quarters of patients received pharmacological treatment during the first 
3 years, with over one-third receiving ≥2 medications of interest, and a notable proportion 
receiving ≥3 medications of interest. Almost one-third of the study population added or 
switched treatment during the 3 years following diagnosis (Table 2). Among patients who 
received pharmacological treatments, around two-thirds (64.5%) had ≥2 treatment episodes, 
while 41.6% had ≥3 episodes (Table, Supplemental Digital Content 6, 
http://links.lww.com/CJP/A483 ).  
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Fewer patients received pharmacological treatment in the second and third years 
following diagnosis (48.4% and 44.4%, respectively) than in the first year (70.2%), and a 
smaller proportion of those treated had multiple episodes of treatment (Table, Supplemental 
Digital Content 7, http://links.lww.com/CJP/A484 ).  
Carbamazepine was received by around half (51.7%) of pharmacologically treated 
patients, while just under half (48.6%) received gabapentin. Just under a quarter received 
pregabalin (23.1%), with a slightly smaller proportion receiving oxcarbazepine (21.3%). The 
other medications (baclofen, duloxetine, and topiramate) were each used by ~10% of the 
overall population; use of these medications was higher among commercial than Medicare 
patients (Fig. 2).  
Among those who started treatment with a pharmacological monotherapy, 
carbamazepine was the most commonly received drug, although only a slightly smaller 
proportion were prescribed gabapentin first line (Table 3). For the most frequently used first-
line monotherapies (carbamazepine, gabapentin, oxcarbazepine, and pregabalin), the duration 
of treatment (from initiation until regimen change) was generally similar among the 
medications (median, ~90 days); median duration tended to be longer for Medicare than 
commercial patients, although means were more similar (Table 3). 
Carbamazepine and gabapentin were also the most frequently prescribed second- and 
third-line pharmacological monotherapies. Duration of second-line monotherapy was 
generally similar to first line, while third-line monotherapy tended to be shorter in duration 
(Tables, Supplemental Digital Content 8, http://links.lww.com/CJP/A485  and 9, 
http://links.lww.com/CJP/A486 ). 
Analysis of treatment switch patterns indicated that patients are most likely to switch 
across classes of therapy, from carbamazepine/oxcarbazepine to pregabalin/gabapentin, and 
vice versa (Figure, Supplemental Digital Content 10, http://links.lww.com/CJP/A487 ). 
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Surgeries and Injections 
Among patients who received a medication of interest before first surgery, the median 
duration, from starting pharmacological treatment until first surgery, was 224 (mean, 322) 
days. The duration was longer for commercial than Medicare patients (Table, Supplemental 
Digital Content 11, http://links.lww.com/CJP/A488 ). 
The majority of patients who had posterior fossa surgery (96.4%), radiosurgery 
(76.6%), and ablative procedures at the Gasserian ganglion (72.8%) had only 1 such episode 
of treatment. The majority receiving peripheral anesthetic injections (55.6%) had ≥2 
injections (Fig. 3).  
Among patients who received surgery during the 3 years following diagnosis, most 
received ≥1 pharmacological treatment before first surgery. A sizeable minority received no 
pharmacological treatments before first surgery, a large proportion of whom (n=81/98) did 
not receive the studied pharmacological treatments at all during the study period (Table 4). 
After first surgery, almost three-quarters of patients received pharmacological treatment 
episodes, with over half continuing to receive pharmacological treatment >90 days after first 
surgery. The proportion of patients who received pharmacological treatment >90 days after 
surgery was lower among those who underwent posterior fossa surgery than among those 
who underwent radiosurgery; nonetheless, the proportion was still substantial (Table 4).  
Radiosurgery was most likely to be performed by neurosurgeons or at neurosurgical 
facilities (57.3% of procedures). Peripheral anesthetic injections were most likely to be 
performed by physicians or facilities specializing in anesthesiology (24.0%) or pain 
management/pain medicine (16.9%), while ablative procedures at the Gasserian ganglion 
were more likely to be administered in an acute care hospital (30.6%) or by neurologists/at 
neurology facilities (21.5%). Data were missing on specialty for most posterior fossa 
surgeries, although this surgery would be performed by a neurosurgeon. 
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Opioids 
Overall, 65.6% of patients received opioids for any reason. A substantial proportion 
(42.9%) received opioids for TN, and 8.2% received them for ≥90 days (Table 2 and Table, 
Supplemental Digital Content 12, http://links.lww.com/CJP/A489 ). Even among those 
without pain comorbidities commonly treated with opioids, a high proportion had 
prescriptions for opioids (Table 2). Around one-fifth of patients who underwent posterior 
fossa surgery, and almost one-third of patients who underwent radiosurgery, continued to 
receive opioids >90 days after surgery (Table, Supplemental Digital Content 12, 
http://links.lww.com/CJP/A489). 
 Among patients who received TN-related opioids, 89.6% received ≥1 nonopioid 
pharmacological treatment episode, 62.7% received ≥2 episodes, and 44.7% received ≥3 
episodes. The majority of patients who received opioids initiated opioid treatment while 
receiving nonopioid pharmacological treatment, while 10.8% received opioids before 
receiving a study drug. The median annual duration of opioid treatment ranged from 17 to 25 
days across the 3 years (mean duration, 39 to 48 days; Table, Supplemental Digital Content 
12, http://links.lww.com/CJP/A489 ). The mean number of opioid prescription refills was 
2.7–2.8 (median 2.0). 
DISCUSSION 
This retrospective database claims analysis suggests that patients with TN in the 
United States frequently receive a variety of pharmacological treatments, surgeries, and 
injections to manage their condition, despite the limited evidence for most of these 
treatments. The most commonly used pharmacological treatment was carbamazepine, the 
only FDA-approved medication for TN; however, it was received by only half of patients, 
and high rates of other pharmacological treatments were also observed, particularly 
gabapentin. A substantial proportion of patients received multiple pharmacological treatment 
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episodes, indicating a high incidence of switching and/or add-on therapy. A relatively high 
proportion of patients underwent surgery within the first 3 years of diagnosis, including 
invasive posterior fossa surgery, and a high proportion continued to receive pharmacological 
treatment >90 days after first surgery (posterior fossa surgery, radiosurgery). Opioid use 
among patients with TN was prevalent, even among those without other pain conditions.  
The severe pain experienced by patients with TN can lead to significant impairment 
of quality of life,
6
 with outcomes for many remaining suboptimal, both because of a lack of 
efficacy and poor tolerability of available therapies. Few advances have been made in the 
treatment of TN in recent years, and at present there are no drugs that have been specifically 
developed for TN.
37
 TN is unusual in being the only neuropathic pain that responds 
significantly to carbamazepine
10
; however, its poor tolerability profile and potential for drug 
interactions may have impacted its use.
11-15,17
 This may explain in part our findings of an 
almost similarly high claim rate of gabapentin, for which there is limited evidence supporting 
efficacy, but which is viewed as having a better safety and tolerability profile than 
carbamazepine.
38
 Further, our finding that carbamazepine and gabapentin were also the most 
frequently prescribed second- and third-line therapies suggests the lack of a well-established 
treatment pathway in TN, particularly in light of findings from other studies that report a 
relatively low use of gabapentin.
25
 Surprisingly, lamotrigine use was very low despite a 
greater body of evidence to support its use in TN than either duloxetine or topiramate.
9,10
  
Of the most commonly used pharmacological treatments, pregabalin and 
carbamazepine had the longest median durations as first-line pharmacological treatment. 
Pregabalin had the longest median duration as second-line pharmacological treatment, which 
could be due to its favorable twice-daily dosage scheme, along with fewer associated side 
effects than the older anticonvulsants. Overall, the median duration of first-line monotherapy 
was around 3 months, suggesting that this is the period over which patients typically 
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determine if a medication is working, although mean durations were longer, suggesting wide 
variations in the data and thus heterogeneity in both the disease course and treatment 
response.  
We observed frequent changes in therapy and use of polypharmacy, with half of 
pharmacologically treated patients receiving ≥2 medications of interest, and around one-fifth 
receiving ≥3 medications of interest, perhaps owing to a lack of efficacy or tolerability of 
individual pharmacological treatments. The use of polypharmacy as a first-line treatment was 
observed despite a general consensus among clinicians to gradually titrate medications over 
time, and to initiate multiple drugs only once monotherapy has failed and prior to surgery.
25
 
Similar treatment patterns, including multiple drug use and only half of patients being 
prescribed carbamazepine, were noted in a prospective study by Zakrzewska et al among 
patients with TN referred to a specialist pain center in the United Kingdom.
6
 In a large UK 
study by Hall et al, 58% of treated patients with TN were prescribed carbamazepine as an 
initial treatment, while substantially fewer were prescribed analgesics and amitriptyline (note 
that the study predated the introduction of gabapentin and pregabalin).
5
 Further, more 
frequent treatment changes occurred when analgesics were used versus carbamazepine. In the 
current study, a notable proportion of patients with a diagnosis of TN did not receive 
pharmacological treatment, a finding in line with the Hall et al study, in which only 66% of 
patients with TN received pharmacological treatment. A smaller Dutch study noted that 97% 
of treated TN patients received a single drug as initial treatment versus 76% as subsequent 
treatment, while 3% were treated with 2 drugs as an initial treatment versus 23% as a 
subsequent treatment. They also found that primary care physicians were less likely to 
prescribe polypharmacy than neurologists for subsequent episodes. Adverse events were 
reported in 11% of first treatment episodes and 15% for subsequent treatment episodes.
24
 
Also of interest is a small study by Taylor et al showing the development of late resistance to 
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carbamazepine in 13% of patients who had a good initial response, which could further 
explain switching of therapy (although this might have been due to the natural history of the 
disorder or due to autoinduction).
39
  
Overall, 12.3% of the study population underwent surgery during the 3 years 
following diagnosis, which is surprising so early in the disease course given the potential for 
remission. Radiosurgery was the most common surgical treatment among Medicare patients, 
while posterior fossa surgery was more common among commercial patients; this difference 
is almost certainly reflective of differences in the age of the populations, with radiosurgery 
being favored among the elderly as the less invasive procedure. Although anesthetic lidocaine 
may be beneficial in the management of acute episodes,
10
 such injections generally have a 
short duration of effect, need repeating and, in the current study, were used by only a small 
percentage of all patients.  
Over half of patients in the current study continued to receive pharmacological 
treatments >90 days after their first surgery, suggesting their pain may not be fully controlled 
by posterior fossa surgery or radiosurgery alone. Of further note is that an unexpectedly high 
proportion of patients (21.6%) did not receive any of the medications of interest before 
surgery, although the majority of these patients (81/98) received no pharmacological 
therapies of interest during the 3-year follow up period. Potential reasons for patients 
progressing to surgery before receiving pharmacological treatment may include a reluctance 
by physicians to prescribe medications such as carbamazepine, which may be poorly 
tolerated and/or a lack of knowledge of guideline recommended treatments. Physicians may 
have a greater familiarity with the use of gabapentin and pregabalin, both of which are used 
to treat a variety of neuropathic pain conditions, in contrast to carbamazepine, which is used 
exclusively for TN. Other reasons may include early referral to neurosurgeons due to 
uncertainty of the diagnosing physician around the management of TN and lack of 
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neurologists with an interest in headaches. It is also possible that some patients received 
treatments other than the 7 specified as of interest, or received treatment before 
documentation of their diagnosis or outside of the insurance network, such as those under the 
care of dental surgeons or orofacial pain experts who entered the system only once they 
required surgery. 
The use of opioids was shown to be prevalent among patients with TN in this study, 
and has been previously noted in the UK study by Zakrzewska et al
6
 and the Dutch study by 
Koopman et al.
24
 This observation is of concern given the lack of evidence for the efficacy of 
opioids in TN and their risk of abuse.
29
 That the use of opioids is high despite these issues 
suggests an absence of effective and tolerable alternatives, and that physicians may be 
prescribing opioids as a rescue therapy. 
TN is an unusual chronic pain due to its episodic, variable and unpredictable nature, 
in terms of both the frequency and severity of attacks and its variable remission periods, 
particularly in the early years of the disease. The length of episodes can vary from 1 to 1462 
days, and it is estimated that 65% are likely to experience a second episode within 5 years.
4
 
Initial remission could account for the fact that a quarter of patients in the current study with 
a TN diagnosis did not receive any of the studied treatments. It could also offer an 
explanation as to why the use of pharmacological treatment decreased in the 2 years after 
diagnosis. However, the decrease also could be reflective of patients proceeding to surgery, 
or switching to opioids or a nonstudied treatment. These potential reasons for stopping 
pharmacological therapy might also explain the reduction in the number of treatment 
episodes, although this could also be due to patients trialling multiple therapies in the first 
year, before continuing on one regimen that they found to be efficacious or tolerable. 
However, it is difficult to draw firm conclusions about the natural history of TN, as the 
relatively short duration of follow-up in the current study (3 years) does not capture the full 
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disease course of TN; further studies are needed with follow-up to examine trends over an 
extended period of time. 
An important consideration for the interpretation of any dataset is the generalizability 
to the overall population with TN. The Truven Health MarketScan database provides a good 
basis for these analyses, given that it covers all regions of the United States and includes 
adults across all ages. However, we note that uninsured individuals and those on Medicaid 
were not captured, and that Medicare patients were likely underrepresented relative to 
commercial patients; Medicare patients included in MarketScan are covered by MediGap or 
Medicare managed care plans, which generally account for only a small proportion of 
Medicare enrollees.  
Rates of comorbidities among patients with TN in this study appear generally 
consistent with the US population. For example, the proportion with diabetes was 12.7%, 
similar to a reported estimate of 11.9% in the general US population.
40
 The prevalence of 
hypertension in the Medicare population (62.4%) was similar to a reported rate of 65.0% in 
the general US population >60 years of age, although the overall prevalence in this study was 
slightly higher (41.2% vs. 29.1%, respectively),
41
 suggestive of a possible association 
between TN and hypertension that has been observed in other studies.
42
 The overall 
prevalence was broadly comparable to a recent UK study of patients with TN, which reported 
that 37.7% of patients with TN had hypertension.
6
 MS is the most frequently associated 
condition with TN; a meta-analysis by Foley et al reported that 4% of patients with MS are 
likely to have TN,
43
 while in this series, 3% of patients had MS. This is compared with a 
prevalence rate of only 58/100,000 (0.058%) in the US population overall.
44
 We noted that 
the proportion of women was slightly higher in this study than for the TN population reported 
in other literature 71.8% vs ~60%
6,8,45, respectively) and the authors’ own practices, most 
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likely due to the fact that women are more likely to access care and typically live longer than 
men. 
Limitations of this study that are inherent to claims analyses include that prescription 
fills do not necessarily reflect treatment usage, and that the analysis is reliant on the accurate 
documentation of diagnosis codes. Consistent with other claims analysis literature, we 
assumed that a claim was TN related if there was a medical claim with a TN diagnosis up to 
30 days before or 7 days after the first prescription fill for each of the 7 medications of 
interest (or all prescriptions for opioids); however, prescriptions do not document the 
diagnosis code directly so we cannot be certain of the reasons for medication use. Dental 
claims were not captured in the database, which may be relevant given that many patients 
initially visit their dentist with TN pain and can receive both medications and irreversible 
treatments.
6
 Additionally, we only evaluated specific medications and surgery/injections of 
interest; however, as these were selected based on expert clinical judgement, we are confident 
they are generally representative of the treatments utilized by patients with TN. The reasons 
for medication switches, discontinuation, and treatment outcomes cannot be fully explained 
with observational studies, and future studies should explore alternative designs to address 
these questions. 
CONCLUSIONS 
This large study provides evidence that patients with TN in the United States 
frequently receive a variety of pharmacological treatments, despite carbamazepine being the 
only approved medication for TN, and international guidelines recommending carbamazepine 
and oxcarbazepine as first-line treatments for pain control. We observed high rates of 
treatment switching and polypharmacy, suggestive of poor efficacy/tolerability of current 
available pharmacologic treatments. A notable proportion of patients undergo surgeries in the 
first 3 years following diagnosis, including patients who did not appear to trial 
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pharmacotherapy prior to surgery. Of concern, a substantial proportion of patients receive 
opioids, despite the lack of evidence for efficacy in TN and potential for abuse. Together, our 
findings indicate a high burden of illness associated with TN and its treatment, a need for 
education of healthcare professionals on the guideline recommended management of TN, and 
a remaining unmet need for therapies with robust efficacy and improved tolerability.  
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Figures 
FIGURE 1. Patient flow diagram.  
Denominators for percentages are the n value for the preceding step. TN, trigeminal neuralgia. 
FIGURE 2. Proportions using pharmacological treatment any time in 3 years, by individual medication, in the 
commercial (A) and Medicare (B) populations.  
Total includes patients started on medications either as monotherapy or part of combination pharmacological 
therapy; the total therefore exceeds 100%. BAC, baclofen; CBZ, carbamazepine; DUL, duloxetine; GBP, 
gabapentin; OXC, oxcarbazepine; PGB, pregabalin; TOP, topiramate. 
FIGURE 3. Number of surgeries/injections among treated patients in the (A) commercial and (B) Medicare 
populations.  
Percentage within the bars represents the percentage breakdown by number of episodes. Denominator (n value) 
= total patients receiving each treatment type. Count of surgeries/injections per patient is based on claims for the 
same type of surgery/injection with unique service dates or admission dates (claims on the same service or 
admission date are grouped as 1 surgery/injection). 
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TABLE 1. Patient Demographics (Index) and Comorbidities (Pre Index) 
 Total 
N=3685 
Commercial 
n=2425 
Medicare 
n=1260 
Mean (SD) age (y) 59.0 (15.3) 49.8 (9.0) 76.8 (7.1) 
Sex, n (%)    
Female 2646 (71.8) 1804 (74.4) 842 (66.8) 
Male 1039 (28.2) 621 (25.6) 418 (33.2) 
Geographical region, n (%)    
Northeast 776 (21.1) 539 (22.2) 237 (18.8) 
North Central 996 (27.0) 538 (22.2) 458 (36.3) 
South 1279 (34.7) 930 (38.4) 349 (27.7) 
West 598 (16.2) 403 (16.6) 195 (15.5) 
Unknown 36 (1.0) 15 (0.6) 21 (1.7) 
Plan indicator, n (%)    
Comprehensive 761 (20.7) 115 (4.7) 646 (51.3) 
PPO 1887 (51.2) 1431 (59.0) 456 (36.2) 
HMO 420 (11.4) 326 (13.4) 94 (7.5) 
Other* 617 (16.7) 553 (22.8) 64 (5.1) 
Comorbidities, n (%)
†
    
Cerebrovascular disease 258 (7.0) 92 (3.8) 166 (13.2) 
Hypertension 1520 (41.2) 734 (30.3) 786 (62.4) 
Diabetes 468 (12.7) 232 (9.6) 236 (18.7) 
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Multiple sclerosis 112 (3.0) 90 (3.7) 22 (1.7) 
Pain related
‡
    
Osteoarthritis 683 (18.5) 335 (13.8) 348 (27.6) 
Lower back pain 667 (18.1) 423 (17.4) 244 (19.4) 
Migraine 342 (9.3) 305 (12.6) 37 (2.9) 
Fibromyalgia 332 (9.0) 259 (10.7) 73 (5.8) 
Stroke-associated pain 297 (8.1) 107 (4.4) 190 (15.1) 
*Other includes exclusive provider organization, point of service (POS), POS with capitation, 
consumer-directed health plan (CDHP), high-deductible health plan (HDHP); data by individual plan type is 
provided in Table, Supplemental Digital Content 4, http://links.lww.com/CJP/A481 . †Based on claims in the 
year before index date; diagnosis codes are listed in Table, Supplemental Digital Content 1. ‡Top 5 of 16 pain 
conditions (full list of 16: diabetic neuropathy, postherpetic neuropathy, stroke-associated pain, lumbar 
radiculopathy, cervical radiculopathy, multiple sclerosis–associated pain, fibromyalgia, osteoarthritis, lower 
back pain, migraine, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthropathy, cancer pain, irritable 
bowel syndrome, interstitial cystitis). 
HMO, health maintenance organization; PPO, preferred provider organizer.  
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TABLE 2. Pharmacological and Nonpharmacological Treatment Use in the 3 Years 
Following Initial TN Diagnosis 
 Total 
N=3685 
Commercial 
n=2425 
Medicare 
n=1260 
Any treatment of interest, n (%) 2752 (74.7) 1789 (73.8) 963 (76.4) 
Pharmacological treatment, n (%)* 2671 (72.5) 1750 (72.2) 921 (73.1) 
Study medications received 
(excluding opioids), n (%) 
   
1 1333 (36.2) 852 (35.1) 481 (38.2) 
2 835 (22.7) 534 (22.0) 301 (23.9) 
3 339 (9.2) 234 (9.6) 105 (8.3) 
≥4 164 (4.5) 130 (5.4) 34 (2.7) 
Pharmacological treatment, ever added 
on or switched, n (%)* 
   
Ever added on or switched 1207 (32.8) 815 (33.6) 392 (31.1) 
Ever added on 755 (20.5) 495 (20.4) 260 (20.6) 
Ever switched 716 (19.4) 500 (20.6) 216 (17.1) 
Posterior fossa surgery, n (%) 222 (6.0) 168 (6.9) 54 (4.3) 
Radiosurgery, n (%) 269 (7.3) 127 (5.2) 142 (11.3) 
Peripheral anesthetic injections, n (%) 207 (5.6) 161 (6.6) 46 (3.7) 
Gasserian ganglion procedures, n (%) 92 (2.5) 61 (2.5) 31 (2.5) 
Received opioids for any reason, n (%) 2418 (65.6) 1635 (67.4) 783 (62.1) 
Received opioids for TN, n (%)
†
 1582 (42.9) 1076 (44.4) 506 (40.2) 
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Opioid use in patients without pain 
comorbidities
‡ 
 
733 (39.3) 
n=1864 
523 (40.8) 
n=1281 
210 (36.0) 
n=583 
Opioid use in patients with pain 
comorbidities
‡
 
849 (46.6) 
n=1821 
553 (48.3) 
n=1144 
296 (43.7) 
n=677 
*Medications of interest: carbamazepine, oxcarbazepine, pregabalin, gabapentin, baclofen, duloxetine, 
topiramate. †Medical claim within −30 to +7 days of an opioid prescription fill. ‡Pain comorbidities: diabetic 
neuropathy, postherpetic neuropathy, stroke-associated pain, lumbar radiculopathy, cervical radiculopathy, 
multiple sclerosis–associated pain, fibromyalgia, osteoarthritis, lower back pain, migraine, rheumatoid arthritis, 
ankylosing spondylitis, psoriatic arthropathy, cancer pain, irritable bowel syndrome, interstitial cystitis. 
TN, trigeminal neuralgia. 
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TABLE 3. Proportion and Duration of First-line Monotherapy by Medication (Among 
Patients Receiving Monotherapy as First-Line Treatment) 
Medication 
Total 
N=2324 
Commercial 
n=1520 Medicare n=804 
Carbamazepine, first-line 
monotherapy, n (%) 
899 (38.7) 584 (38.4) 315 (39.2) 
Duration 
(days) 
Median (IQR) 90 (30–370) 58 (30–245) 145 (39–644) 
Mean (SD) 271 (361) 223 (329) 359 (401) 
Gabapentin, first-line monotherapy, 
n (%) 
740 (31.8) 466 (30.7) 274 (34.1) 
Duration 
(days)  
Median (IQR) 86 (30–286) 69 (30–265) 112 (30–366) 
Mean (SD) 246 (342) 224 (324) 285 (367) 
Oxcarbazepine, first-line 
monotherapy, n (%) 
271 (11.7) 165 (10.9) 106 (13.2) 
Duration 
(days)  
Median (IQR) 80 (30–387) 65 (30–384) 124 (30–463) 
Mean (SD) 270 (354) 252 (346) 300 (365) 
Pregabalin, first-line monotherapy, 
n (%) 
204 (8.8) 137 (9.0) 67 (8.3) 
Duration 
(days) 
Median (IQR) 90 (30–341) 59 (28–223) 149 (32–558) 
Mean (SD) 266 (370) 232 (359) 335 (384) 
Topiramate, first-line monotherapy, 
n (%) 
106 (4.6) 90 (5.9) 16 (2.0) 
Duration Median (IQR) 31 (23–193) 38 (23–260) 30 (21–71) 
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(days) Mean (SD) 233 (367) 250 (379) 137 (283) 
Duloxetine, first-line monotherapy, 
n (%) 
67 (2.9) 53 (3.5) 14 (1.7) 
Duration 
(days) 
Median (IQR) 99 (27–368) 99 (28–363) 108 (21–368) 
Mean (SD) 308 (394) 304 (386) 320 (435) 
Baclofen, first-line monotherapy, n 
(%) 
37 (1.6) 25 (1.6) 12 (1.5) 
Duration 
(days) 
Median (IQR) 30 (13–178) 30 (20–256) 20 (4–30) 
Mean (SD) 100 (146) 130 (165) 38 (61) 
IQR, interquartile range. 
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TABLE 4. Among Those With Surgery, Pharmacological Treatment Episodes Before and After 
First Surgery 
 
 
Total 
N=454† 
Commercial 
n=271 
Medicare 
n=183 
Pharmacological treatment episodes before first surgery, n (%) 
0 98 (21.6) 48 (17.7) 50 (27.3) 
1 123 (27.1) 64 (23.6) 59 (32.2) 
≥2 233 (51.3) 159 (58.7) 74 (40.4) 
Pharmacological treatment 
episodes after first surgery, 
n (%) 
   
0 116 (25.6) 62 (22.9) 54 (29.5) 
1 134 (29.5) 80 (29.5) 54 (29.5) 
≥2 204 (44.9) 129 (47.6) 75 (41.0) 
Pharmacological treatment >90 days 
after first surgery, n (%) 
237 (52.2) 148 (54.6) 89 (48.6) 
Posterior fossa surgery* 85 (42.3) 
n=201 
71 (45.2) 
n=157 
14 (31.8) 
n=44 
Radiosurgery* 152 (60.1) 
n=253 
77 (67.5) 
n=114 
75 (54.0) 
n=139 
*Denominator (n value) = total number with surgery type. †Of the overall population, 81 of 454 patients 
did not receive any pharmacological treatment during the 3-year follow up period. 
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Supplemental Digital Content 1. Comorbidity Diagnosis Codes 
Comorbidity Diagnosis code(s) 
Depression  2962, 2963, 311, F33, F32 
Anxiety 3000, 3001, 3002, 3003, 3004, 3005, 3006, 3007, 3008, F423, 
F429, F422, F428, F341, F488, F481, F4522, F4521 
Insomnia 30742, 30741, 3270, 78051, 78052, F5102, F5109, F5103, 
F5101, F5109, G4730, G4700 
Stroke 430, 431, 432, 433, 434, 436 
Hypertension 401, 402, 403, 404, 405 
Multiple sclerosis 340 
Diabetes 250 
Pain conditions 
Diabetic neuropathy 2506, 3572  
Postherpetic neuropathy 05310, 05311, 05312, 05313, 05314, 05319 
Stroke-associated pain 430, 431, 432, 433, 434, 436, 437, 3380  
Lumbar radiculopathy 7244 
Cervical radiculopathy 7234 
Multiple sclerosis–
associated pain 
340, 3380 
Fibromyalgia 7291 
Osteoarthritis 7150, 7151, 7152, 7158, 7159, 7210, 7211, 7212, 7213, 
72141, 72142 
Lower back pain 72283, 72402, 7242, 7245, 7248 
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Migraine 3460, 3461, 3462, 3468, 3469  
Rheumatoid arthritis 7140, 7141, 7142, 71430, 71431, 71432, 71433, 7144, 71481 
Ankylosing spondylitis 7200, 7201, 7202, 72081, 72089 
Psoriatic arthropathy 696 
Cancer pain 3383  
Irritable bowel syndrome 5641 
Interstitial cystitis 5951 
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Supplemental Digital Content 2. Definitions Used to Define Pharmacological Treatment 
Episodes 
Add-on therapy A claim for a new medication, filled with ≥30-day overlap 
in prescription coverage relative to the prior treatment 
episode (based on days’ supply) 
Treatment switch A claim for a new medication, filled with <30-day overlap 
in prescription coverage relative to the prior treatment 
episode 
Discontinuation A gap of ≥90 days between fills (from the last day of supply 
to the next fill date) 
Treatment episode Any unique pharmacological treatment regimen 
(monotherapy or combination), with the end of each episode 
defined by a change in regimen (add-on, switch, or 
discontinuation) 
Duration of treatment 
episode 
Based on the time from the first day of supply to last day of 
supply (for discontinuations) or the fill date of a new 
treatment episode (for treatment add-on or switch) 
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Supplemental Digital Content 3. Surgery/Injection Treatment Codes  
Code type Code Procedure 
Posterior fossa surgery 
CPT 61450 Craniectomy, subtemporal, for section, compression, or 
decompression of sensory root of Gasserian ganglion 
CPT 61458 Craniectomy, suboccipital, for exploration or 
decompression of cranial nerves 
CPT 61460 Craniectomy, suboccipital, for section of ≥1 cranial nerves 
ICD 0402 04.02 Division of trigeminal nerve 
ICD 0405 Gasserian ganglionectomy 
ICD 0441 04.41 Decompression of trigeminal nerve root 
ICD 0124 01.24 Other craniotomy 
ICD 0139 01.39 Other incision of brain 
ICD 0159 01.59 Other excision or destruction of lesion or tissue of 
brain 
ICD 0299 02.99 Other operations on skull, brain, and cerebral 
meninges 
ICD 0404 04.04 Other incision of cranial and peripheral nerves 
ICD 0407 04.07 Other excision or avulsion of cranial and peripheral 
nerves 
ICD 0419 04.19 Other diagnostic procedures on cranial and 
peripheral nerves and ganglia 
ICD 0449 04.49 Other peripheral nerve or ganglion decompression 
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or lysis of adhesions 
ICD 046 04.6 Transposition of cranial and peripheral nerves 
ICD 0499 04.99 Other operations on cranial and peripheral nerves 
ICD 0529 05.29 Other sympathectomy and ganglionectomy 
Radiosurgery 
CPT 61796 Stereotactic radiosurgery (particle beam, gamma ray, or 
linear accelerator), 1 simple cranial lesion 
CPT 61797 Stereotactic radiosurgery (particle beam, gamma ray, or 
linear accelerator), each additional cranial lesion, simple 
(list separately in addition to code for primary procedure) 
CPT 61798 Stereotactic radiosurgery (particle beam, gamma ray, or 
linear accelerator), 1 complex cranial lesion 
CPT 61799 Stereotactic radiosurgery (particle beam, gamma ray, or 
linear accelerator), each additional cranial lesion, complex 
(list separately in addition to code for primary procedure) 
CPT 61790 Creation of lesion by stereotactic method, percutaneous, 
by neurolytic agent (eg, alcohol, thermal, electrical, 
radiofrequency), Gasserian ganglion 
CPT 61791 Creation of lesion by stereotactic method, percutaneous, 
by neurolytic agent (eg, alcohol, thermal, electrical, 
radiofrequency), trigeminal medullary tract 
CPT 77371 Radiation treatment delivery, stereotactic radiosurgery, 
complete course of treatment of cranial lesion(s) 
consisting of 1 session, multisource cobalt 60 based  
HCPC G0173 Stereo radiosurgery, complete 
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HCPC G0251 Collimator changes and custom plugging, fractionated 
treatment, all lesions, per session, maximum 5 sessions per 
course of treatment 
HCPC G0339 Complete course of therapy in 1 session or first session of 
fractionated treatment 
HCPC G0340 Delivery including collimator changes and custom 
plugging, fractionated treatment, all lesions, per session, 
second through fifth sessions, maximum 
ICD 9224 92.24 Teleradiotherapy using photons 
ICD 9229 92.29 Other radiotherapeutic procedure 
ICD 9230 92.30 Stereotactic radiosurgery, not otherwise specified 
ICD 9231 92.31 Single-source photon radiosurgery 
ICD 9232 92.32 Multisource photon radiosurgery 
ICD 9233 92.33 Particulate radiosurgery 
Peripheral anesthetic injection 
CPT 64400 Destruction by neurolytic agent, trigeminal nerve; 
supraorbital, infraorbital, mental, or inferior alveolar 
branch  
ICD 0480 04.80 Peripheral nerve injection, not otherwise specified 
ICD 0481 04.81 Injection of anesthetic into peripheral nerve for 
analgesia 
ICD 0489 04.89 Injection of other agent, except neurolytic 
ICD 0531 05.31 Injection of anesthetic into sympathetic nerve for 
analgesia 
ICD 0539 05.39 Other injection into sympathetic nerve or ganglion 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is
 an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution,
 and reproduction in any medium, provided the original work is properly cited...
ICD 8398 83.98 Injection of locally acting therapeutic 
ICD 9929 99.29 Injection or infusion of other therapeutic or 
prophylactic substance 
CPT 64612 Chemodenervation of muscle(s); muscle(s) innervated by 
facial nerve, unilateral (eg, for blepharospasm, hemifacial 
spasm) 
Ablative procedures at the Gasserian ganglion   
CPT 64600 Destruction by neurolytic agent, trigeminal nerve, 
supraorbital, infraorbital, mental, or inferior alveolar 
branch 
CPT 64605 Destruction by neurolytic agent, trigeminal nerve, second 
and third division branches at foramen ovale 
CPT 64610 Destruction by neurolytic agent, trigeminal nerve, second 
and third division branches at foramen ovale under 
radiologic monitoring 
ICD 0532 05.32 Injection of neurolytic agent into sympathetic nerve 
CPT, Current Procedural Terminology; HCPC, Healthcare Common Procedure Code; ICD, 
International Classification of Diseases. 
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Supplemental Digital Content 4. Proportion of Patients by Health Care Plan Type  
Plan indicator, n 
(%) 
Total 
N=3685 
Commercial 
n=2425 
Medicare 
n=1260 
Comprehensive 761 (20.7) 115 (4.7) 646 (51.3) 
PPO 1887 (51.2) 1431 (59.0) 456 (36.2) 
HMO 420 (11.4) 326 (13.4) 94 (7.5) 
EPO 30 (0.8) 29 (1.2) 1 (0.1) 
POS 300 (8.1) 257 (10.6) 43 (3.4) 
POS with capitation 14 (0.4) 14 (0.6) – 
CDHP 149 (4.0) 147 (6.1) 2 (0.2) 
HDHP 71 (1.9) 70 (2.9) 1 (0.1) 
Missing 53 (1.4) 36 (1.5) 17 (1.4) 
CDHP, consumer-directed health plan; EPO, exclusive provider organization; HDHP, 
high-deductible health plan; HMO, health maintenance organization; PPO, preferred provider 
organization; POS, point of service. 
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Supplemental Digital Content 5. Treatment Switch Patterns Among Patients Treated With 
Pharmacological Treatment or Surgeries  
Treatment type, n (%) 
First treatment 
n=2752 
Second 
treatment 
n=1795 
Thrid 
treatment 
n=1223 
Monotherapy* 2324 (84.4) 1131 (63.0) 795 (65.0) 
Polypharmacy*  330 (12.0) 541 (30.1) 332 (27.1) 
Surgery (posterior fossa surgery 
or radiosurgery only) 
98 (3.6) 123 (6.9) 96 (7.8) 
*Medications of interest: carbamazepine, oxcarbazepine, pregabalin, gabapentin, 
baclofen, duloxetine, topiramate  
  
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is
 an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution,
 and reproduction in any medium, provided the original work is properly cited...
  
Supplemental Digital Content 6. Number of Pharmacological Treatment Episodes Among 
Patients Treated With Pharmacological Treatment Over the 3-Year Study Period  
Treatment 
episodes, n (%) 
Total 
N=2671 
Commercial 
n=1750 
Medicare 
n=921 
1 948 (35.5) 618 (35.3) 330 (35.8) 
2 613 (23.0) 398 (22.7) 215 (23.3) 
3 415 (15.5) 275 (15.7) 140 (15.2) 
4 231 (8.7) 145 (8.3) 86 (9.3) 
5 172 (6.4) 112 (6.4) 60 (6.5) 
6 to 10 268 (10.0) 182 (10.4) 86 (9.3) 
≥11 24 (0.9) 20 (1.1) 4 (0.4) 
 
  
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is
 an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution,
 and reproduction in any medium, provided the original work is properly cited...
  
Supplemental Digital Content 7. Pharmacological Treatment Episodes by Year of Follow-
up Among the Overall Population  
Treatment 
episodes, n (%) 
Total 
N=3685 
Commercial 
n=2425 
Medicare 
n=1260 
Year 1    
0 1099 (29.8) 734 (30.3) 365 (29.0) 
1 1383 (37.5) 878 (36.2) 505 (40.1) 
2 624 (16.9) 424 (17.5) 200 (15.9) 
≥3 579 (15.7) 389 (16.0) 190 (15.1) 
Year 2    
0 1900 (51.6) 1323 (54.6) 577 (45.8) 
1 1235 (33.5) 740 (30.5) 495 (39.3) 
2 319 (8.7) 204 (8.4) 115 (9.1) 
≥3 231 (6.3) 158 (6.5) 73 (5.8) 
Year 3    
0 2049 (55.6) 1412 (58.2) 637 (50.6) 
1 1133 (30.8) 690 (28.5) 443 (35.2) 
2 274 (7.4) 174 (7.2) 100 (7.9) 
≥3 229 (6.2) 149 (6.1) 80 (6.3) 
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Supplemental Digital Content 8. Proportion and Duration of Second-Line Monotherapy by 
Medication  
Medication 
Total 
N=1130 
Commercial 
n=750 
Medicare 
n=380 
Carbamazepine, second-line 
monotherapy, n (%) 
338 (29.9) 211 (28.1) 127 (33.4) 
Duration 
(days) 
Median (IQR) 90 (30–269) 80 (30–210) 145 (35–371) 
Mean (SD) 204 (252) 174 (230) 252 (279) 
Gabapentin, second-line monotherapy, 
n (%) 
364 (32.2) 231 (30.8) 133 (35) 
Duration 
(days)  
Median (IQR) 90 (30–253) 64 (30–198) 134 (30–366) 
Mean (SD) 199 (255) 172 (241) 245 (272) 
Oxcarbazepine, second-line 
monotherapy, n (%) 
165 (14.6) 110 (14.7) 55 (14.5) 
Duration 
(days)  
Median (IQR) 90 (30–370) 85 (30–342) 103 (36–547) 
Mean (SD) 248 (305) 231 (297) 282 (319) 
Pregabalin, second-line monotherapy, 
n (%) 
138 (12.2) 96 (12.8) 42 (11.1) 
Duration 
(days) 
Median (IQR) 133 (30–344) 121 (30–339) 181 (79–388) 
Mean (SD) 256 (295) 239 (290) 294 (307) 
Topiramate, second-line monotherapy, 
n (%) 
47 (4.2) 43 (5.7) 4 (1.1) 
Duration Median (IQR) 61 (30–128) 65 (30–130) 30 (30–38) 
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(days) Mean (SD) 121 (186) 129 (192) 34 (8) 
Duloxetine, second-line monotherapy, 
n (%) 
41 (3.6) 32 (4.3) 9 (2.4) 
Duration 
(days) 
Median (IQR) 138 (47–403) 137 (39–369) 322 (104–540) 
Mean (SD) 300 (339) 286 (343) 348 (340) 
Baclofen, second-line monotherapy, n 
(%) 
37 (3.3) 27 (3.6) 10 (2.6) 
Duration 
(days) 
Median (IQR) 41 (30–144) 42 (25–153) 32 (30–90) 
Mean (SD) 142 (238) 172 (272) 59 (50) 
IQR, interquartile range. 
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Supplemental Digital Content 9. Proportion and Duration of Third-line Monotherapy by 
Medication  
Medication 
Total 
N=796 
Commercial 
n=508 
Medicare 
n=288 
Carbamazepine, third-line 
monotherapy, n (%) 
247 (31.0) 155 (30.5) 92 (31.9) 
Duration 
(days) 
Median (IQR) 33 (30–107) 30 (30–104) 39 (30–124) 
Mean (SD) 108 (172) 91 (134) 135 (219) 
Gabapentin, third-line monotherapy, 
n (%) 
238 (29.9) 143 (28.2) 95 (33.0) 
Duration 
(days)  
Median (IQR) 46 (30–109) 45 (30–109) 47 (30–110) 
Mean (SD) 96 (131) 92 (118) 103 (149) 
Oxcarbazepine, third-line 
monotherapy, n (%) 
98 (12.3) 60 (11.8) 38 (13.2) 
Duration 
(days)  
Median (IQR) 36 (30–90) 30 (23–90) 51 (30–90) 
Mean (SD) 111 (204) 107 (212) 117 (193) 
Pregabalin, third-line monotherapy, n 
(%) 
97 (12.2) 61 (12.0) 36 (12.5) 
Duration 
(days) 
Median (IQR) 34 (30–158) 34 (30–140) 37 (8–239) 
Mean (SD) 122 (168) 105 (131) 152 (216) 
Topiramate, third-line monotherapy, 
n (%) 
50 (6.3) 44 (8.7) 6 (2.1) 
Duration Median (IQR) 30 (28–75) 30 (22–75) 41 (30–58) 
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(days) Mean (SD) 68 (86) 71 (91) 49 (27) 
Duloxetine, third-line monotherapy, 
n (%) 
33 (4.2) 20 (3.9) 13 (4.5) 
Duration 
(days) 
Median (IQR) 86 (30–187) 45 (30–155) 159 (82–337) 
Mean (SD) 156 (174) 114 (134) 222 (211) 
Baclofen, third-line monotherapy, n 
(%) 
33 (4.2) 25 (4.9) 8 (2.8) 
Duration 
(days) 
Median (IQR) 47 (28–156) 75 (28–156) 39 (19–143) 
Mean (SD) 140 (193) 156 (211) 93 (116) 
IQR, interquartile range. 
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Supplemental Digital Content 10. Pharmacological treatment switch/add on patterns, by 
medication, in the commercial (A) and Medicare (B) populations.  
BAC, baclofen; CBZ, carbamazepine; DUL, duloxetine; GBP, gabapentin; OXC, 
oxcarbazepine; PGB, pregabalin; TOP, topiramate.  
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Supplemental Digital Content 11. Duration in Days, From First TN Diagnosis to First 
Surgery Among Patients Who Underwent Surgery, and From Initial Pharmacological 
Treatment to First Surgery Among Patients Who Received Pharmacological Treatment 
Before Surgery 
 Total  
N=454 
Commercial  
n=271 
Medicare  
n=183 
Days from TN 
diagnosis to first 
surgery 
   
Median (IQR) 226 (76–514) 300 (96–570) 133 (55–419) 
Mean (SD) 329 (302) 364 (300) 277 (298) 
Days from starting 
pharmacological 
treatment to first 
surgery* 
n=356 n=223 n=133 
Median (IQR) 224 (81–488) 292 (95–539) 132 (63–399) 
Mean (SD) 322 (292) 355 (294) 266 (281) 
*Among patients who received pharmacological treatment before surgery (17 patients 
received surgery before pharmacological treatment; 81 patients did not receive 
pharmacological treatment and were excluded from this analysis).  
IQR, interquartile range; TN, trigeminal neuralgia.  
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Supplemental Digital Content 12. Overall and TN-Related Opioid Use* 
 Total 
N=3685 
Commercial 
n=2425 
Medicare 
n=1260 
Opioids (any use), n (%) 2418 (65.6) 1635 (67.4) 783 (62.1) 
≥90 days of opioid use over 3 years, n (%) 693 (18.8) 470 (19.4) 223 (17.7) 
TN-related opioid use, n (%)* 1582 (42.9) 1076 (44.4) 506 (40.2) 
≥90 days of opioid use over 3 years, n (%) 303 (8.2) 223 (9.2) 80 (6.3) 
TN-related opioid use* n=1582 n=1076 n=506 
Nonopioid pharmacological treatment episodes, 
n (%) 
   
0 165 (10.4) 112 (10.4) 53 (10.5) 
1 425 (26.9) 290 (27.0) 135 (26.7) 
2 285 (18.0) 181 (16.8) 104 (20.6) 
≥3 707 (44.7) 493 (45.8) 214 (42.3) 
Opioid use initiation relative to 
pharmacological treatment episodes, n (%) 
   
Did not receive pharmacological treatment 165 (10.4) 112 (10.4) 53 (10.5) 
Initiated opioids before first 
pharmacological treatment  
171 (10.8) 129 (12.0) 42 (8.3) 
Initiated opioids after last pharmacological 
treatment  
68 (4.3) 43 (4.0) 25 (4.9) 
Initiated opioids concurrently with 
pharmacological treatment 
1178 (74.5) 792 (73.6) 386 (76.3) 
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 Denominators vary 
Opioid use in patients who did receive surgery 
within 3 years, n (%) 
310 (68.3) 
n=454 
206 (76.0) 
n=271 
104 (56.8) 
n=183 
Opioid use in patients who did not receive 
surgery within 3 years, n (%) 
1272 (39.4) 
n=3231 
870 (40.4) 
n=2154 
402 (37.3) 
n=1n,077 
Opioid use >90 days after posterior fossa 
surgery, n (%)  
44 (21.9) 
n=201 
35 (22.3) 
n=157 
9 (20.5) 
n=44) 
Opioid use >90 days after radiosurgery, n (%) 76 (30.0) 
n=253 
40 (35.1) 
n=114 
36 (25.9) 
n=139 
Opioid use in patients without OA, RA, and 
lower back pain  
1039 (40.7) 
n=2553 
757 (42.6) 
n=1779 
282 (36.4) 
n=774 
Opioid use in patients with OA, RA, and lower 
back pain 
543 (48.0) 
n=1132 
319 (49.4) 
n=646 
224 (46.1) 
n=486 
Duration of opioid treatment by year (days)    
Year 1 
Median  17 17 19 
Mean (SD) 39 (51) 40 (54) 35 (42) 
 n=1309 n=911 n=398 
Year 2 
Median  22 24 20 
Mean (SD) 44 (56) 50 (63) 33 (39) 
 n=517 n=342 n=175 
Year 3 
Median  25 30 20 
Mean (SD) 48 (62) 53 (68) 37 (47) 
 n=451 n=310 n=141 
*Opioids with a TN claim −30 to +7 days.  
OA, osteoarthritis; RA, rheumatoid arthritis; TN, trigeminal neuralgia. 
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